These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12739987)

  • 1. Aminoglycoside dosages and nephrotoxicity: quantitative relationships.
    Rougier F; Ducher M; Maurin M; Corvaisier S; Claude D; Jelliffe R; Maire P
    Clin Pharmacokinet; 2003; 42(5):493-500. PubMed ID: 12739987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside.
    Murry KR; McKinnon PS; Mitrzyk B; Rybak MJ
    Pharmacotherapy; 1999 Nov; 19(11):1252-60. PubMed ID: 10555931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ototoxicity caused by once- and twice-daily administration of amikacin in rabbits.
    Pavlidis P; Nikolaidis V; Gouveris H; Papadopoulos E; Kekes G; Kouvelas D
    Int J Pediatr Otorhinolaryngol; 2010 Apr; 74(4):361-4. PubMed ID: 20089318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
    Kiel PJ; Lo M; Stockwell D; Patel GP
    Am J Ther; 2008; 15(2):131-6. PubMed ID: 18356633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminoglycoside nephrotoxicity: modeling, simulation, and control.
    Rougier F; Claude D; Maurin M; Sedoglavic A; Ducher M; Corvaisier S; Jelliffe R; Maire P
    Antimicrob Agents Chemother; 2003 Mar; 47(3):1010-6. PubMed ID: 12604535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of haemodialysis as a protective technique for preventing high daily dose amikacin nephrotoxicity: an experimental study in an ovine model.
    Pouzot-Nevoret C; Magnin M; Ayoub JY; Bourguignon L; Maire P; Wertz D; Goy-Thollot I; Barthélemy A; Boselli E; Allaouchiche B; Bonnet-Garin JM
    Int J Antimicrob Agents; 2017 Aug; 50(2):148-154. PubMed ID: 28689868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective comparative study of gentamicin- and amikacin-induced nephrotoxicity in patients with normal baseline renal function.
    Sweileh WM
    Fundam Clin Pharmacol; 2009 Aug; 23(4):515-20. PubMed ID: 19709328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum albumin and the increased risk of amikacin nephrotoxicity.
    Contreras AM; Ramírez M; Cueva L; Alvarez S; de Loza R; Gamba G
    Rev Invest Clin; 1994; 46(1):37-43. PubMed ID: 8079062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
    Rybak MJ; Abate BJ; Kang SL; Ruffing MJ; Lerner SA; Drusano GL
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1549-55. PubMed ID: 10390201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobramycin and amikacin nephrotoxicity. Value of serum creatinine versus urinary concentration of beta-2-microglobulin.
    Gatell JM; SanMiguel JG; Zamora L; Araujo V; Castells C; Moreno A; Jimenez de Anta MT; Marin JL; Elena M; Ballesta A
    Nephron; 1985; 41(4):337-43. PubMed ID: 3906418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity induced by gentamicin and amikacin.
    Smith CR; Maxwell RR; Edwards CQ; Rogers JF; Lietman PS
    Johns Hopkins Med J; 1978 Mar; 142(3):85-90. PubMed ID: 342789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
    Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
    J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
    Stass H; Corkery K; Gribben D; Eldon MA
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amikacin use and therapeutic drug monitoring in adults: do dose regimens and drug exposures affect either outcome or adverse events? A systematic review.
    Jenkins A; Thomson AH; Brown NM; Semple Y; Sluman C; MacGowan A; Lovering AM; Wiffen PJ;
    J Antimicrob Chemother; 2016 Oct; 71(10):2754-9. PubMed ID: 27494904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity.
    Langhendries JP; Battisti O; Bertrand JM; François A; Darimont J; Ibrahim S; Tulkens PM; Bernard A; Buchet JP; Scalais E
    Dev Pharmacol Ther; 1993; 20(3-4):220-30. PubMed ID: 7828457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients.
    Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M
    Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes.
    Bacopoulou F; Markantonis SL; Pavlou E; Adamidou M
    J Crit Care; 2003 Jun; 18(2):107-13. PubMed ID: 12800120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.
    Pérez V; Saénz D; Madriz J; Harhay M; Feoli J; Castro M; Odio C
    Int J Infect Dis; 2011 Aug; 15(8):e569-75. PubMed ID: 21733727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.